ATE173274T1 - Basen-tumorzellen behandlungsverfahren - Google Patents
Basen-tumorzellen behandlungsverfahrenInfo
- Publication number
- ATE173274T1 ATE173274T1 AT91305582T AT91305582T ATE173274T1 AT E173274 T1 ATE173274 T1 AT E173274T1 AT 91305582 T AT91305582 T AT 91305582T AT 91305582 T AT91305582 T AT 91305582T AT E173274 T1 ATE173274 T1 AT E173274T1
- Authority
- AT
- Austria
- Prior art keywords
- tumor cells
- treatment methods
- chelating
- cells treatment
- usually
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Networks Using Active Elements (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54228190A | 1990-06-21 | 1990-06-21 | |
| US66926991A | 1991-03-14 | 1991-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE173274T1 true ATE173274T1 (de) | 1998-11-15 |
Family
ID=27066985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91305582T ATE173274T1 (de) | 1990-06-21 | 1991-06-20 | Basen-tumorzellen behandlungsverfahren |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5690928A (de) |
| EP (2) | EP0467536B1 (de) |
| JP (1) | JPH0721000B2 (de) |
| KR (1) | KR920000332A (de) |
| AT (1) | ATE173274T1 (de) |
| AU (1) | AU645094B2 (de) |
| CA (1) | CA2044858A1 (de) |
| DE (1) | DE69130466T2 (de) |
| DK (1) | DK0467536T3 (de) |
| ES (1) | ES2122968T3 (de) |
| FI (1) | FI913058A (de) |
| IE (1) | IE912130A1 (de) |
| IL (1) | IL98528A0 (de) |
| NO (1) | NO303579B1 (de) |
| PT (1) | PT98048B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207798B1 (en) * | 1989-08-03 | 2001-03-27 | Merck & Co., Inc. | Modified PE40 toxin fusion proteins |
| WO1993000917A1 (en) * | 1991-07-05 | 1993-01-21 | Seragen, Inc. | Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis |
| EP0665746A4 (de) * | 1992-10-07 | 1996-03-13 | Merck & Co Inc | FORMULIERUNG MIT KONTROLLIERTEM pH-WERT FÜR DIE INSTILLATION VON TGF ALPHA PE 40 ab IN DIE HARNBLASE. |
| CA2371241A1 (en) * | 1999-04-26 | 2000-11-02 | Stem Cell Pharmaceuticals, Inc. | Tgf-.alpha. polypeptides, functional fragments and methods of use therefor |
| CA2380635A1 (en) * | 1999-08-19 | 2001-02-22 | Stem Cell Pharmaceuticals, Inc. | Tgf-.alpha. polypeptides, functional fragments and methods of use therefor |
| US20020193301A1 (en) * | 1999-08-19 | 2002-12-19 | Stem Cell Pharmaceuticals, Inc. | TGF-alpha polypeptides, functional fragments and methods of use therefor |
| CU23077A1 (es) * | 2000-12-06 | 2005-08-17 | Centro Inmunologia Molecular | Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas |
| CN100417414C (zh) * | 2003-04-30 | 2008-09-10 | 苏黎世大学 | 免疫毒素在制备治疗头颈鳞状上皮细胞癌或膀胱癌药物中的应用 |
| CN100436481C (zh) * | 2003-08-18 | 2008-11-26 | 中国医学科学院基础医学研究所 | 含腺病毒E4orf4蛋白的靶向性抗肿瘤融合蛋白 |
| GB0321344D0 (en) * | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE038768T2 (hu) * | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| SI2117520T1 (sl) | 2006-12-14 | 2019-01-31 | Abraxis Bioscience, Llc | Zdravljenje raka dojk glede na status hormonskih receptorjev z nano delci, ki zajemajo taksan |
| RU2016119999A (ru) | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
| NZ602635A (en) | 2010-03-29 | 2014-12-24 | Abraxis Bioscience Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| US9399071B2 (en) | 2010-06-04 | 2016-07-26 | Abraxis Bioscience, Llc | Methods of treatment of pancreatic cancer |
| WO2015048901A1 (en) | 2013-10-02 | 2015-04-09 | Viventia Bio Inc. | Anti-epcam antibodies and methods of use |
| ITUD20130127A1 (it) * | 2013-10-04 | 2015-04-05 | Danieli Off Mecc | Impianto siderurgico per la produzione di prodotti metallici lunghi e relativo metodo di produzione |
| JP6847846B2 (ja) | 2015-03-12 | 2021-03-24 | セセン バイオ，インコーポレイテッド | Ｅｐｃａｍ陽性膀胱癌を標的とする投薬戦略 |
| US10576163B2 (en) | 2015-03-12 | 2020-03-03 | Viventia Bio Inc. | Methods of treatment for EpCAM positive bladder cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3369466D1 (en) * | 1982-05-12 | 1987-03-05 | Harvard College | Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof |
| FI82266C (fi) * | 1982-10-19 | 1991-02-11 | Cetus Corp | Foerfarande foer framstaellning av il-2 -mutein. |
| US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
| US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
| EP0154434B1 (de) * | 1984-02-17 | 1993-01-27 | Genentech, Inc. | Menschlicher Transformationswachstumsfaktor und Vorläufer oder Fragment hiervon, Zellen, DNA, Vektoren und Verfahren zu ihrer Herstellung, Zusammensetzungen und Produkte, die diese enthalten, sowie davon abgeleitete Antikörper und Diagnostizierverfahren |
| US4785079A (en) * | 1984-11-09 | 1988-11-15 | The Salk Institute For Biological Studies | Isolation of fibroblast growth factor |
| IN165717B (de) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4892827A (en) * | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| DK0383599T3 (da) * | 1989-02-17 | 1996-08-05 | Merck & Co Inc | Protein-anticancermiddel |
| IL93723A (en) * | 1989-03-22 | 1997-02-18 | Merck & Co Inc | Cystein modified truncated pseudomonas exotoxin A |
-
1991
- 1991-06-17 IL IL98528A patent/IL98528A0/xx unknown
- 1991-06-18 CA CA002044858A patent/CA2044858A1/en not_active Abandoned
- 1991-06-20 FI FI913058A patent/FI913058A/fi not_active Application Discontinuation
- 1991-06-20 DE DE69130466T patent/DE69130466T2/de not_active Expired - Fee Related
- 1991-06-20 AT AT91305582T patent/ATE173274T1/de active
- 1991-06-20 AU AU79189/91A patent/AU645094B2/en not_active Ceased
- 1991-06-20 EP EP91305582A patent/EP0467536B1/de not_active Expired - Lifetime
- 1991-06-20 NO NO912418A patent/NO303579B1/no not_active IP Right Cessation
- 1991-06-20 ES ES91305582T patent/ES2122968T3/es not_active Expired - Lifetime
- 1991-06-20 PT PT98048A patent/PT98048B/pt not_active IP Right Cessation
- 1991-06-20 DK DK91305582T patent/DK0467536T3/da active
- 1991-06-20 IE IE213091A patent/IE912130A1/en unknown
- 1991-06-20 EP EP98106872A patent/EP0868920A3/de not_active Withdrawn
- 1991-06-21 KR KR1019910010286A patent/KR920000332A/ko not_active Application Discontinuation
- 1991-06-21 JP JP3266746A patent/JPH0721000B2/ja not_active Expired - Lifetime
-
1994
- 1994-04-11 US US08/224,422 patent/US5690928A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0467536B1 (de) | 1998-11-11 |
| JPH0721000B2 (ja) | 1995-03-08 |
| NO912418L (no) | 1991-12-23 |
| EP0467536A2 (de) | 1992-01-22 |
| AU645094B2 (en) | 1994-01-06 |
| AU7918991A (en) | 1992-01-02 |
| NO912418D0 (no) | 1991-06-20 |
| CA2044858A1 (en) | 1991-12-22 |
| IL98528A0 (en) | 1992-07-15 |
| US5690928A (en) | 1997-11-25 |
| EP0868920A3 (de) | 1999-02-10 |
| KR920000332A (ko) | 1992-01-29 |
| PT98048A (pt) | 1992-04-30 |
| EP0467536A3 (en) | 1992-09-16 |
| DE69130466T2 (de) | 1999-06-02 |
| FI913058A0 (fi) | 1991-06-20 |
| DE69130466D1 (de) | 1998-12-17 |
| ES2122968T3 (es) | 1999-01-01 |
| PT98048B (pt) | 1998-11-30 |
| EP0868920A2 (de) | 1998-10-07 |
| FI913058A (fi) | 1991-12-22 |
| DK0467536T3 (da) | 1999-07-26 |
| NO303579B1 (no) | 1998-08-03 |
| IE912130A1 (en) | 1992-01-01 |
| JPH0592999A (ja) | 1993-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE173274T1 (de) | Basen-tumorzellen behandlungsverfahren | |
| KR900013961A (ko) | 기억력 및 학습력 증강 또는 인식 또는 정신장해 치료용 d-시클로세린 및 d-알라닌 함유 조성물 | |
| NO943703D0 (no) | Sammensetninger og fremgangsmåter for bestemmelse av proteinstrukturer | |
| PT96068A (pt) | Processo para a producao de proteina biologicamente activa | |
| ES2227527T3 (es) | Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada. | |
| FR2562539B1 (fr) | Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands | |
| DK1014996T3 (da) | Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser | |
| BR9811716A (pt) | Análogos de ciclosporina deuterados e o seu emprego como agentes de modulação imunológica | |
| DK0447585T4 (da) | Fremgangsmåde til fremstilling af et intravenøst tolerant immunglobulin-G-præparat | |
| ATE135712T1 (de) | Polypeptid, dessen verfahren zur herstellung und dieses enthaltende pharmazeutische zusammensetzung und deren benutzung | |
| DE69407272D1 (de) | Verfahren zum reinigen von 20 cs)-camptothecin | |
| DE69229944D1 (de) | Verwendung von N-Acylaminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von Mastzellerkrankungen | |
| ATE121727T1 (de) | Chelatbildner, die eine ortho-bindende funktionelle gruppe besitzen und komplexe davon. | |
| ATE123947T1 (de) | Echinacea-extrakte, verfahren zur herstellung und zubereitungen, die sie enthalten. | |
| ATE131490T1 (de) | Verfahren zur herstellung von gereinigten albuminlösungen | |
| FR2707638B1 (fr) | Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique. | |
| PT93178A (pt) | Agente proteico anticanceroso | |
| DE69122960D1 (de) | Verfahren und zubereitungen für die behandlung von verletzungen | |
| ATE167871T1 (de) | Verfahren zur herstellung von vancomycin | |
| ATE215599T1 (de) | Superoxid dismutase-4 | |
| ES1003038U (es) | Dispositivo corrector de patologia vertebral | |
| ATE5406T1 (de) | 2-methyl-3-(2,4,6-trijod-3-(1morpholino[thylidenamino)-benzamido)propionitril, verfahren zu dessen herstellung und dessen verwendung als zwischenprodukt. | |
| Kalinichenko | Initial Microperiphyton Production in the Reservoir/Coolant of an Atomic Power Station(Pervichnaia Produktsiia Mikroperifitona Vodoema-Okhladitelya Atommoi Elektrostantsii) | |
| DE3685988D1 (de) | Verwendung von "naftidrofuryl" zur behandlung von neuropathien. | |
| ATE31315T1 (de) | Inklusionscomplexe von n-(1-phenylaethyl)-3,3diphenylpropylamin bzw. dessen hydrochlorid mit cyclodextrin, verfahren zur herstellung dieser inklusionskomplexe sowie diese inklusionskomplexe enthaltende pharmazeutische praeparate. |